Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhu Boce Biology Technology Co., Ltd. is a China-based biotechnology company focused on the development and manufacture of high-quality biological reagents and diagnostic raw materials. Established in 2018, the company specializes in producing recombinant proteins, antibodies, and molecular biology enzymes used primarily in the In Vitro Diagnostics (IVD) industry and life science research. Wuhu Boce Biology operates a comprehensive platform for protein expression and purification, as well as antibody screening and production. Their service offerings include customized CRO solutions for protein engineering and immunological assay development. The company serves a global clientele, providing essential components for the detection of infectious diseases, cardiac markers, and tumor biomarkers. By leveraging advanced bioprocessing technologies, Wuhu Boce Biology aims to provide cost-effective and reliable tools for clinical diagnostics and pharmaceutical R&D.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wuhu Boce Biology.